Who is sponsoring NCT04350021?

NCT04350021 is sponsored by Vastra Gotaland Region.

What drugs are being tested in NCT04350021?

Interventions in NCT04350021: Capecitabine, Cyclophosphamide.

What condition does NCT04350021 study?

NCT04350021 studies Breast Cancer Metastatic, Chemotherapy Effect.

Is NCT04350021 still recruiting?

NCT04350021 is currently completed. Last updated 17 January 2024.

Last reviewed 2024-01-17 · How we verify

NCT04350021: METRO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer

Completed Last updated 17 January 2024

What this trial tests

trial testing Capecitabine, Cyclophosphamide in Breast Cancer Metastatic in 40 participants. Completed in 30 October 2023.

Timeline

1 March 2019

Primary endpoint
30 October 2023

30 October 2023

Quick facts

Lead sponsor	Vastra Gotaland Region
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 March 2019
Primary completion	30 October 2023
Estimated completion	30 October 2023
Sites	1 location across Sweden

Drugs / interventions tested

Capecitabine, Cyclophosphamide — full drug profile →

Conditions studied

Breast Cancer Metastatic — all drugs for Breast Cancer Metastatic →
Chemotherapy Effect — all drugs for Chemotherapy Effect →

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Breast Cancer Metastatic or Chemotherapy Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC) is used as a palliative regiment with the aim to prolong and improve quality of life. The effect of LDMC is not fully elucidated. The aim is to evaluate the effect of LDMC with Capecitabine and Cyclophosphamide (CX) and to discover new potential predictive markers and potential markers for monitoring treatment effect.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Inhibition of Metastasis by Polypyridyl Ru(II) Complexes through Modification of Cancer Cell Adhesion - <i>In Vitro</i> Functional and Molecular Studies.
Gurgul I, Janczy-Cempa E, Mazuryk O, Lekka M, et al · · 2022 · cited 13× · PMID 35895090 · DOI 10.1021/acs.jmedchem.2c00580
Metronomic Chemotherapy in Elderly Patients.
Bandini A, Calabrò PF, Banchi M, Orlandi P, et al · · 2024 · cited 5× · PMID 38448722 · DOI 10.1007/s11912-024-01505-w
Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer - efficacy, tolerability and quality of life results from the phase II METRO trial.
Larsson K, Adra J, Klint L, Linderholm B. · · 2024 · cited 2× · PMID 39236341 · DOI 10.1016/j.breast.2024.103795

Verify or expand the search:

Other recruiting trials for Breast Cancer Metastatic

Currently open trials in the same condition.

NCT07292168 — A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Ex · Phase 1, PHASE2 · recruiting
NCT06616987 — Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer · Phase 2 · recruiting
NCT06750484 — Trial of Trastuzumab Deruxtecan in Previously Treated HER2 · Phase 2 · recruiting
NCT06784921 — To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Pa · recruiting
NCT07154563 — Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Ca · recruiting

Other Vastra Gotaland Region trials

Trials by the same sponsor.

NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
NCT07472335 — Home-based Acute Care for Older Persons Initiated by the Emergency Medical and Ambulance Services - a Retrospective Obse · not yet recruiting
NCT07246577 — The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant C · recruiting
NCT07449338 — Prospective Cohort Study of Response and Tolerability of Accelerated Intermittent Theta-burst Stimulation (1W-AiTBS) · not yet recruiting
NCT07334340 — Modified vs Standard CDED: Evaluation of a Nordic Adaptation of Nutritional Therapy in Paediatric Crohn's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04350021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vastra Gotaland Region
Last refreshed: 17 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04350021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing